Nexplanon , a single-rod contraceptive implant containing the progestin etonogestrel, has now been approved for prevention of pregnancy for up to 5 years. It was previously approved for up to 3 years of use.
Med Lett Drugs Ther. 2026 Mar 2; 68(1749):40 doi:10.58347/tml.2026.1749b
Nexplanon , a single-rod contraceptive implant containing the progestin etonogestrel, has now been approved for prevention of pregnancy for up to 5 years. It was previously approved for up to 3 years of use.
Miudella (Sebela), a copper intrauterine device (IUD), has been approved by the FDA for prevention of pregnancy for up to 3 years. Miudella is the second copper IUD to be approved in the US; ParaGard , which…
Med Lett Drugs Ther. 2025 Jun 9; 67(1730):89-90 doi:10.58347/tml.2025.1730a
Miudella (Sebela), a copper intrauterine device (IUD), has been approved by the FDA for prevention of pregnancy for up to 3 years. Miudella is the second copper IUD to be approved in the US; ParaGard , which contains more copper and is approved for up to 10 years of use, was approved in 1984. Four hormonal IUDs (Mirena, Liletta, Skyla, Kyleena) that release the progestin levonorgestrel are also available for pregnancy prevention (see Table 2).
The FDA has approved Twirla (Agile Therapeutics), a transdermal contraceptive patch containing the estrogen ethinyl estradiol and the progestin levonorgestrel, for use in women with a BMI <30 kg/m 2 . It is…
Med Lett Drugs Ther. 2021 Feb 8; 63(1617):17-8
The FDA has approved Twirla (Agile Therapeutics), a transdermal contraceptive patch containing the estrogen ethinyl estradiol and the progestin levonorgestrel, for use in women with a BMI <30 kg/m 2 . It is the second contraceptive patch to become available in the US; Xulane , a patch that delivers ethinyl estradiol and the progestin norelgestromin, has been available since 2014.
The FDA has approved Phexxi (Evofem), a nonhormonal prescription-only vaginal gel containing lactic acid, citric acid, and potassium bitartrate, for prevention of pregnancy. The gel is intended for on-demand…
Med Lett Drugs Ther. 2020 Aug 24; 62(1605):129-32
The FDA has approved Phexxi (Evofem), a nonhormonal prescription-only vaginal gel containing lactic acid, citric acid, and potassium bitartrate, for prevention of pregnancy. The gel is intended for on-demand contraception; it is not effective when used after intercourse. It was previously approved for use as a vaginal lubricant (Amphora) , but was never marketed.
In our article on Slynd (Med Lett Drugs Ther 2020; 62:18), the drospirenone-only oral contraceptive, we mentioned that drospirenone has antiandrogenic activity that could improve acne and antimineralocorticoid…
Med Lett Drugs Ther. 2020 Mar 23; 62(1594):48
In our article on Slynd (Med Lett Drugs Ther 2020; 62:18), the drospirenone-only oral contraceptive, we mentioned that drospirenone has antiandrogenic activity that could improve acne and antimineralocorticoid activity that could cause hyperkalemia. We should have added that concurrent use of drospirenone with other drugs that increase potassium levels, such as the anti-androgen aldosterone receptor antagonist spironolactone ( Aldactone , and generics), which is often used off-label for treatment of acne, can increase the risk of hyperkalemia.
The FDA has approved a progestin-only oral contraceptive ("minipill") containing drospirenone ( Slynd – Exeltis). All other progestin-only oral contraceptives available in the US contain norethindrone (…
Med Lett Drugs Ther. 2020 Feb 10; 62(1591):18-9
The FDA has approved a progestin-only oral contraceptive ("minipill") containing drospirenone ( Slynd – Exeltis). All other progestin-only oral contraceptives available in the US contain norethindrone ( Camila , and others). Progestin-only oral contraceptives are similar in efficacy to combination oral contraceptives. They are used predominantly by breastfeeding women and by those in whom estrogen is poorly tolerated or contraindicated. Combination oral contraceptives containing drospirenone and ethinyl estradiol have been available for years.
Annovera (TherapeuticsMD), a contraceptive vaginal ring that releases segesterone acetate, a synthetic progestin, and ethinyl estradiol, was approved by the FDA in 2018 and is now available. It is the first…
Med Lett Drugs Ther. 2019 Dec 16; 61(1587):197-8
Annovera (TherapeuticsMD), a contraceptive vaginal ring that releases segesterone acetate, a synthetic progestin, and ethinyl estradiol, was approved by the FDA in 2018 and is now available. It is the first product to contain segesterone and the second vaginal ring to become available in the US; NuvaRing , which delivers etonogestrel and ethinyl estradiol, was the first. Unlike NuvaRing , which requires use of a new ring each month, the Annovera ring can be used for an entire year, but it must be removed for one week each month.
Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also highly…
Med Lett Drugs Ther. 2018 Oct 8; 60(1557):161-8
Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also highly effective in preventing pregnancy. When used alone, barrier and fertility-based methods generally have higher failure rates than other methods.
Essure (Bayer) is the only nonsurgical, permanent contraceptive available in the US. The coil-like devices are placed hysteroscopically in both fallopian tubes and, after several months, scar tissue causes…
Med Lett Drugs Ther. 2018 May 21; 60(1547):90
Essure (Bayer) is the only nonsurgical, permanent contraceptive available in the US. The coil-like devices are placed hysteroscopically in both fallopian tubes and, after several months, scar tissue causes tubal occlusion. 1 In 2016, the FDA required Bayer to revise the device's labeling to include a patient decision checklist and a boxed warning about the risks of uterine and fallopian tube perforation, migration of the device to the abdominal or pelvic cavity, persistent pain, and hypersensitivity reactions. Some women were apparently not being informed of these risks before implantation of the device, which can only be removed surgically. As a result, the FDA is now restricting the sale and distribution of Essure to healthcare providers who agree to review the "Patient-Doctor Discussion Checklist – Acceptance of Risk and Informed Decision Acknowledgement" with their patients before implantation. The checklist includes information about the device, its safety, and its effectiveness. Patients and physicians must sign the checklist before the device is implanted. From its approval in 2002 through 2017, the FDA received 26,773 medical device reports related to Essure . The most common adverse effects reported with its use were abdominal pain, heavier menses/menstrual irregularities, headache, fatigue, and weight fluctuations. Nickel allergy, migration of the device, dislodged or dislocated device, and device breakage have also been reported. During this time period, there were 1863 pregnancies (365 live births, 875 miscarriages, 623 unspecified) and 13 deaths (8 adults, 4 infants after live birth, 1 unspecified). 2 Bayer states that more than 750,000 women have received Essure worldwide, but the device was taken off the market in the United Kingdom, the Netherlands, Finland, and Canada, and Bayer stopped sales of Essure outside the US altogether in September 2017. Some women with contraindications or intolerance to hormonal contraceptives are also poor candidates for laparoscopic tubal ligation, leaving them few options for highly effective contraception. For these women, in the US, Essure remains an option. Choice of contraceptives. Med Lett Drugs Ther 2015; 57:127. FDA activities: Essure. Available at: www.fda.gov. Accessed May 10, 2018. Download complete U.S. English article
The FDA has approved Kyleena (Bayer), an intrauterine device (IUD) that releases the synthetic progestin levonorgestrel, for prevention of pregnancy. It is the fourth levonorgestrel-releasing IUD to be…
Med Lett Drugs Ther. 2017 Feb 27; 59(1515):38-9
The FDA has approved Kyleena (Bayer), an intrauterine device (IUD) that releases the synthetic progestin levonorgestrel, for prevention of pregnancy. It is the fourth levonorgestrel-releasing IUD to be approved in the US. Like Mirena , which has been available since 2000, Kyleena is approved for up to 5 years of use.
Implants, intrauterine devices (IUDs), and sterilization are the most effective contraceptive methods available. Pills, patches, rings, and injectables, when used correctly, are also highly effective in…
Med Lett Drugs Ther. 2015 Sep 14; 57(1477):127-32
Implants, intrauterine devices (IUDs), and sterilization are the most effective contraceptive methods available. Pills, patches, rings, and injectables, when used correctly, are also highly effective in preventing pregnancy. Barrier and fertility-based methods have the highest rates of failure.
The FDA has approved Liletta , an intrauterine device (IUD) that releases the synthetic progestin levonorgestrel, for prevention of pregnancy for up to 3 years. The fourth IUD to be approved in the US, and the…
Med Lett Drugs Ther. 2015 Jul 6; 57(1472):99-100
The FDA has approved Liletta , an intrauterine device (IUD) that releases the synthetic progestin levonorgestrel, for prevention of pregnancy for up to 3 years. The fourth IUD to be approved in the US, and the third that releases levonorgestrel, Liletta is comarketed by Actavis and Medicines360, a nonprofit women's health pharmaceutical company. The wholesale cost of Liletta is similar to that of other IUDs (see Table 1), but the manufacturer offers programs that significantly reduce the cost for commercially-insured patients and clinics serving low-income women.
The FDA has approved Quartette (Teva), an extended-cycle combination oral contraceptive containing increasing doses of the estrogen ethinyl estradiol (EE) combined with the progestin levonorgestrel (LNG). The…
Med Lett Drugs Ther. 2013 Jul 8; 55(1420):54-5
The FDA has approved Quartette (Teva), an extended-cycle combination oral contraceptive containing increasing doses of the estrogen ethinyl estradiol (EE) combined with the progestin levonorgestrel (LNG). The rationale is that a gradual increase in the EE dose may reduce unscheduled bleeding or spotting, a common adverse effect of extended-cycle oral contraceptives.
The progestin levonorgestrel is available over the counter for emergency contraception as two 0.75-mg tablets taken 12 hours apart (generic formulations of Plan B ) and as a single 1.5-mg tablet taken once (…
Med Lett Drugs Ther. 2013 Jun 24; 55(1419):52
The progestin levonorgestrel is available over the counter for emergency contraception as two 0.75-mg tablets taken 12 hours apart (generic formulations of Plan B ) and as a single 1.5-mg tablet taken once ( Plan B One-Step , and generics). A third emergency contraceptive, ulipristal ( Ella – Watson), is available with a prescription. 1 It appears that, pursuant to a court order, Plan B One-Step (but not the generic products), which was previously available over the counter from a pharmacist only for women 17 years and older, will now be available directly from pharmacy shelves with no age restrictions. EMERGENCY CONTRACEPTION — Currently used hormonal methods of emergency contraception, which apparently mainly prevent or delay ovulation, can prevent 50-80% of pregnancies. 2 They should be started as soon as possible within 72 hours after unprotected intercourse. One study found that taking levonorgestrel as late as 120 hours after unprotected intercourse could still be effective. 3 Many oral contraceptives can be used in doses suitable for emergency contraception. All are recommended for use in 2 doses 12 hours apart, but given the effectiveness of a single dose of levonorgestrel 1.5 mg in Plan B One-Step , taking the tablets all at once might be an option. Patients who vomit within 1 hour of administration can repeat the dose. A copper IUD inserted within 5 days after intercourse can also provide emergency contraception. ADVERSE EFFECTS — Nausea and vomiting occur less frequently with levonorgestrel alone than with estrogen-progestin combinations. Headache, abdominal pain and breast tenderness have been reported with either progestin-only or combination oral contraceptives. No fetal malformations caused by unsuccessful use of hormones for emergency contraception have been reported. 1. Ella: a new emergency contraceptive. Med Lett Drugs Ther 2011; 53:3. 2. DT Baird. Emergency contraception: how does it work? Reprod Biomed Online 2009; 18 suppl 1:32. 3. H von Hertzen et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 2002; 360:1803. Download complete U.S. English article
The FDA recently approved Skyla (Bayer), the first new intrauterine device (IUD) in the US in 12 years. It releases levonorgestrel, a synthetic progestin, over a period of 3 years. A table summarizing…
Med Lett Drugs Ther. 2013 Mar 18; 55(1412):21-2
The FDA recently approved Skyla (Bayer), the first new intrauterine device (IUD) in the US in 12 years. It releases levonorgestrel, a synthetic progestin, over a period of 3 years. A table summarizing contraceptive methods available in the US appears on page 22.
The FDA has announced that combination hormonal contraceptives (CHCs) containing the synthetic progestin drospirenone ( Yaz, Yasmin, Beyaz, Safyral, and others) may be associated with a higher risk of…
Med Lett Drugs Ther. 2012 Apr 30; 54(1389):33
The FDA has announced that combination hormonal contraceptives (CHCs) containing the synthetic progestin drospirenone ( Yaz, Yasmin, Beyaz, Safyral, and others) may be associated with a higher risk of thromboembolism than CHCs containing other progestins. 1 The new warning was based partly on an unpublished, FDA-funded, retrospective study that found a 1.7-times higher risk of venous thromboembolism among US women who used a CHC that contained drospirenone than among women whose CHC contained levonorgestrel, norgestimate or norethindrone as the progestin component. 2 As with all retrospective studies, unknowable confounding factors, such as why doctors prescribed one progestin over the other, could have distorted the results. All CHCs increase the risk of venous thromboembolism; whether the progestin component affects the risk has been controversial. The Medical Letter and several other reviews and consensus statements have found no convincing evidence of an increased risk with drospirenone. 3-5 1. FDA Drug Safety Communication: Updated information about the risk of blood clots in women taking birth control pills containing drospirenone. Available at www.fda.gov/Drugs/DrugSafety/ucm299305.htm. Accessed April 23, 2012. 2. FDA. Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints. Available at www.fda.gov/downloads/Drugs/DrugSafety/ucm277384. Accessed April 23, 2012. 3. Combination oral contraceptives and the risk of venous thromboembolism. Med Lett Drugs Ther 2010; 52:23. 4. RL Reid. Oral contraceptives and venous thromboembolism: pill scares and public health. J Obstet Gynaecol Can 2011; 33:1150. 5. L Manzoli et al. Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis. Drug Saf 2012; 35: 191. Download complete U.S. English article
Nexplanon (Merck), a modified version of the contraceptive implant Implanon (Merck), is now available in the US. Nexplanon contains 68 mg of the progestin etonogestrel and is bioequivalent to Implanon . Both…
The choice of which contraceptive to use may vary from one stage of reproductive life to another. Intrauterine devices (IUDs), progestin implants and sterilization are the most effective contraceptive methods…
Treat Guidel Med Lett. 2010 Dec; 8(100):89-96
The choice of which contraceptive to use may vary from one stage of reproductive life to another. Intrauterine devices (IUDs), progestin implants and sterilization are the most effective contraceptive methods available to women. Hormonal contraceptives, when used correctly, are also highly effective in preventing pregnancy. Barrier and fertility-based methods have the highest rate of failure.
Combination oral contraceptives increase the risk of venous thromboembolism (VTE). Their benefits, in addition to preventing pregnancy, include lowering the risk of ovarian and endometrial cancer, reducing…
Med Lett Drugs Ther. 2010 Mar 22; 52(1334):23-4
Combination oral contraceptives increase the risk of venous thromboembolism (VTE). Their benefits, in addition to preventing pregnancy, include lowering the risk of ovarian and endometrial cancer, reducing dysfunctional uterine bleeding and increasing serum hemoglobin concentrations. Are these benefits worth the risk? And are some combination oral contraceptives safer than others?
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.
Treat Guidel Med Lett. 2009 Aug; 7(84):57-64
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.
The FDA has announced that it will lower the age for over-the-counter access to the emergency contraceptive Plan B 1 from 18 to 17 years old. In a randomized, controlled trial, the two 0.75-mg levonorgestrel…
Med Lett Drugs Ther. 2009 May 18; 51(1312):40
The FDA has announced that it will lower the age for over-the-counter access to the emergency contraceptive Plan B 1 from 18 to 17 years old. In a randomized, controlled trial, the two 0.75-mg levonorgestrel tablets in Plan B , taken 12 hours apart beginning within 72 hours after unprotected intercourse, decreased the overall pregnancy rate to 1.1% (11/976) of women who requested emergency contraception. 2 The sooner the drug is taken after coitus, the more effective it is. Nausea and vomiting can occur with Plan B . Fetal malformations have not been associated with pregnancies that occurred despite use of levonorgestrel-only emergency contraception. 3 1. Emergency contraception OTC. Med Lett Drugs Ther 2004; 46:10. 2. Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet 1998; 352:428. 3. L Zhang et al. Pregnancy outcome after levonorgestrel-only emergency contraception failure: a prospective cohort study. Hum Reprod 2009 Mar 31 (epub). Download: U.S. English
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium…
Treat Guidel Med Lett. 2008 Nov; 6(75):75-82
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium acnes promote development of acne lesions by secreting chemotactic factors that attract leukocytes to the follicle, causing inflammation.
The drugs of choice for treatment of some fungal infections are listed in the tables. Some of the indications and dosages recommended here have not been approved by the FDA. Other guidelines are available from…
Treat Guidel Med Lett. 2008 Jan; 6(65):1-8
The drugs of choice for treatment of some fungal infections are listed in the tables. Some of the indications and dosages recommended here have not been approved by the FDA. Other guidelines are available from the Infectious Diseases Society of America ( www.idsociety.org ).
Transdermal, transvaginal and intrauterine hormone delivery systems have made highly effective contraceptive products more convenient to use. New oral contraceptive options include regimens with fewer or…
Treat Guidel Med Lett. 2007 Dec; 5(64):101-8
Transdermal, transvaginal and intrauterine hormone delivery systems have made highly effective contraceptive products more convenient to use. New oral contraceptive options include regimens with fewer or shorter hormone-free intervals.
Implanon (Organon), an implantable contraceptive containing the progestin etonogestrel, has been approved by the FDA. Two other implantable contraceptives, Norplant and Jadelle , which both contain…
Med Lett Drugs Ther. 2006 Oct 9; 48(1245):83-4
Implanon (Organon), an implantable contraceptive containing the progestin etonogestrel, has been approved by the FDA. Two other implantable contraceptives, Norplant and Jadelle , which both contain levonorgestrel, are FDA-approved but not marketed in the US.
Three new combination oral contraceptives (COCs) with shortened hormone-free intervals, Seasonique , Loestrin 24 Fe and Yaz , have recently been approved by the FDA. All 3 are derivatives of older products.
Med Lett Drugs Ther. 2006 Sep 25; 48(1244):77-8
Three new combination oral contraceptives (COCs) with shortened hormone-free intervals, Seasonique , Loestrin 24 Fe and Yaz , have recently been approved by the FDA. All 3 are derivatives of older products.
The FDA has approved over-the-counter (OTC) sales of Plan B (Duramed), an emergency contraceptive package that contains two 0.75-mg tablets of levonorgestrel, to women ≥18 years old. Younger women still…
Med Lett Drugs Ther. 2006 Sep 11; 48(1243):75
The FDA has approved over-the-counter (OTC) sales of Plan B (Duramed), an emergency contraceptive package that contains two 0.75-mg tablets of levonorgestrel, to women ≥18 years old. Younger women still require a prescription. In one trial, two levonorgestrel 0.75-mg tablets taken 12 hours apart, the first within 72 hours after unprotected intercourse, decreased the pregnancy rate to 1%, compared to an expected rate of 8% (Task Force on Postovulatory Methods of Fertility Regulation, Lancet 1998; 352:428) . How high doses of a progestin taken after coitus prevent pregnancy is unclear; they may interfere with ovulation, fertilization or implantation. Nausea and vomiting can occur. The drug will not terminate an established pregnancy. No fetal malformations have been reported after unsuccessful use. Plan B will not be available OTC until the end of the year, according to the manufacturer, and the OTC price is not yet available. The retail price for the prescription product varies from about $25 to $40. In order to enforce the age restriction, the drug will be kept behind the pharmacist’s counter, and a valid photo ID will be required. Download: U.S. English
An extended-release formulation of carbamazepine, available since 1997 for treatment of epilepsy, has now been approved under a new name, Equetro , for acute mania and mixed episodes of bipolar disorder.…
Med Lett Drugs Ther. 2005 Mar 28; 47(1205):27-8
An extended-release formulation of carbamazepine, available since 1997 for treatment of epilepsy, has now been approved under a new name, Equetro , for acute mania and mixed episodes of bipolar disorder. Although the drug was effective in some patients for up to 6 months, it has not been approved for maintenance treatment. Carbamazepine has not been shown to be more effective than lithium or valproate, and it can cause serious adverse effects.
The drugs of choice for treatment of some fungal infections are listed in the table that begins on page 8. Some of the indications and dosages recommended here have not been approved by the FDA.
Treat Guidel Med Lett. 2005 Feb; 3(30):7-14
The drugs of choice for treatment of some fungal infections are listed in the table that begins on page 8. Some of the indications and dosages recommended here have not been approved by the FDA.
Tuberculosis (TB) is still a problem in the United States, even though the incidence continues to decline in most of the country (MMWR Morbid Mortal Wkly Rep 2004; 53:209). Treatment of TB can be divided into…
Treat Guidel Med Lett. 2004 Dec; 2(28):83-2
Tuberculosis (TB) is still a problem in the United States, even though the incidence continues to decline in most of the country (MMWR Morbid Mortal Wkly Rep 2004; 53:209). Treatment of TB can be divided into treatment of latent infection diagnosed by a positive PPD and treatment of active clinical TB. Guidelines with detailed management recommendations are available from the US Centers for Disease Control and Prevention (CDC) (MMWR Morbid Mortal Wkly Rep 2003; 52RR-11:1).
In recent years, several new contraceptive options have become available in the United States. Novel hormone delivery systems such as transdermal, transvaginal and intrauterine devices have improved the…
Treat Guidel Med Lett. 2004 Aug; 2(24):55-62
In recent years, several new contraceptive options have become available in the United States. Novel hormone delivery systems such as transdermal, transvaginal and intrauterine devices have improved the convenience of highly effective contraceptive products. Like oral contraceptives and most barrier contraceptives, these devices do not protect against sexually transmitted diseases.
An FDA Advisory Committee has recommended over-the-counter (OTC) marketing of Plan B (Barr), an emergency contraceptive "pill pack" that contains two 0.75-mg tablets of levonorgestrel to be taken 12 hours…
Med Lett Drugs Ther. 2004 Feb 2; 46(1175):10-1
An FDA Advisory Committee has recommended over-the-counter (OTC) marketing of Plan B (Barr), an emergency contraceptive "pill pack" that contains two 0.75-mg tablets of levonorgestrel to be taken 12 hours apart ( Medical Letter 2000; 42:10 ). Plan B is one of two FDA-approved products for this indication. The Preven Emergency Contraceptive Kit ( Medical Letter, 40:102, 1998 ) includes four tablets, each containing 0.25 mg of levonorgestrel and 50 ╡g of ethinyl estradiol; these are taken 2 at a time 12 hours apart (the "Yuzpe regimen") and are available only by prescription.
Zolmitriptan ( Zomig - AstraZeneca) nasal spray was recently approved by the FDA for treatment of migraine. It is the second selective serotonin receptor agonist ("triptan") to become available as a nasal…
Med Lett Drugs Ther. 2004 Jan 19; 46(1174):7-8
Zolmitriptan ( Zomig - AstraZeneca) nasal spray was recently approved by the FDA for treatment of migraine. It is the second selective serotonin receptor agonist ("triptan") to become available as a nasal spray; sumatriptan has been available in this form since 1997. Some patients with migraine cannot take tablets because of nausea and vomiting, and nasal sprays are more convenient than subcutaneous injections.
A high-intensity, narrow-band blue light ( ClearLight -Lumenis) approved by the FDA for treatment of moderate inflammatory acne vulgaris has been featured in some stories in fashion magazines. This review…
Med Lett Drugs Ther. 2003 Jun 23; 45(1159):50-1
A high-intensity, narrow-band blue light ( ClearLight -Lumenis) approved by the FDA for treatment of moderate inflammatory acne vulgaris has been featured in some stories in fashion magazines. This review describes the etiology and treatment of acne, as well as the mechanism of action, clinical studies, adverse effects, dosage and cost of the drug.
Polycystic ovary syndrome (PCOS), an endocrine abnormality characterized by hyperandrogenism and anovulation, affects 5-10% of women of reproductive age in the US. It is often accompanied by obesity and…
Med Lett Drugs Ther. 2003 Apr 28; 45(1155):35-6
Polycystic ovary syndrome (PCOS), an endocrine abnormality characterized by hyperandrogenism and anovulation, affects 5-10% of women of reproductive age in the US. It is often accompanied by obesity and insulin resistance. In recent years, antidiabetic drugs, although not approved for such use by the FDA, have been tried for treatment of this disorder. This review describes the effectiveness of metformin and the thiazolidinediones in women with PCOS. Also included is a dosage and cost table for some insulin-sensitizing drugs.
An oral contraceptive ( Yasmin - Berlex) containing 3 mg of drospirenone and 30 mcg of ethinyl estradiol is being promoted as having a low incidence of adverse effects.
Med Lett Drugs Ther. 2002 Jun 24; 44(1133):55-7
An oral contraceptive ( Yasmin - Berlex) containing 3 mg of drospirenone and 30 mcg of ethinyl estradiol is being promoted as having a low incidence of adverse effects.
A transdermal contraceptive patch ( Ortho Evra Ortho-McNeil) has been approved by the FDA. Each 20 cm 2 patch contains 6 mg of the progestin norelgestromin (the active metabolite of norgestimate) and…
Med Lett Drugs Ther. 2002 Jan 21; 44(1122):8
A transdermal contraceptive patch ( Ortho Evra Ortho-McNeil) has been approved by the FDA. Each 20 cm 2 patch contains 6 mg of the progestin norelgestromin (the active metabolite of norgestimate) and 0.75 mg of ethinyl estradiol.
The FDA had approved an intrauterine contraceptive device that releases the synthetic progestin levonorgestrel over a period of five years. The device has been available in Europe for 10 years.
Med Lett Drugs Ther. 2001 Jan 22; 43(1096):7-8
The FDA had approved an intrauterine contraceptive device that releases the synthetic progestin levonorgestrel over a period of five years. The device has been available in Europe for 10 years.
Modafinil (Provigil), a benzhydryl sulfinylacetamide non-amphetamine stimulant that has been used in Europe since 1995, has now been approved by the FDA for treatment of excessive daytime sleepiness associated…
Med Lett Drugs Ther. 1999 Mar 26; 41(1049):30-1
Modafinil (Provigil), a benzhydryl sulfinylacetamide non-amphetamine stimulant that has been used in Europe since 1995, has now been approved by the FDA for treatment of excessive daytime sleepiness associated with narcolepsy.
Rifapentine, a long-acting analog of rifampin developed in the 1960's, has received an accelerated approval from the FDA for oral use, with at least one other drug, in the treatment of pulmonary tuberculosis.
Med Lett Drugs Ther. 1999 Feb 26; 41(1047):21-2
Rifapentine, a long-acting analog of rifampin developed in the 1960's, has received an accelerated approval from the FDA for oral use, with at least one other drug, in the treatment of pulmonary tuberculosis.
Tizanidine ( Zanaflex - Athena Neurosciences) has been approved by the US Food and Drug Administration for oral treatment of increased muscle tone associated with spasticity. It has been available in Europe…
Med Lett Drugs Ther. 1997 Jul 4; 39(1004):62-3
Tizanidine ( Zanaflex - Athena Neurosciences) has been approved by the US Food and Drug Administration for oral treatment of increased muscle tone associated with spasticity. It has been available in Europe and Japan for 12 years as a short-term muscle relaxant.
Topiramate ( Topamax - Ortho-McNeil) has been approved by the US Food and Drug Administration (FDA) for oral use as an adjunct to other drugs in adult patients with partial seizures. Since this diagnostic…
Med Lett Drugs Ther. 1997 May 23; 39(1001):51-2
Topiramate ( Topamax - Ortho-McNeil) has been approved by the US Food and Drug Administration (FDA) for oral use as an adjunct to other drugs in adult patients with partial seizures. Since this diagnostic category includes the largest number of patients with refractory epilepsy, new drugs with antiepileptic activity are usually tried first for this indication. Topiramate (toe pyre' a mate) is a structurally unique agent chemically related to the D-enantiomer of fructose.
Itraconazole (Sporanox - Janssen), an oral antifungal triazole that has been available in the USA since 1992 for treatment of deep fungal infections (Medical Letter, 35:7, 1993), is now being marketed for…
Med Lett Drugs Ther. 1996 Jan 19; 38(966):5-6
Itraconazole (Sporanox - Janssen), an oral antifungal triazole that has been available in the USA since 1992 for treatment of deep fungal infections (Medical Letter, 35:7, 1993), is now being marketed for treatment of dermatophyte infections of the toenails, with or without fingernail involvement.
Tuberculosis (TB) continues to be a major problem in the United States, particularly in areas where drug resistance is common (Morbid Mortal Weekly Rep, 44:387, May 26, 1995). Since poor compliance is the most…
Med Lett Drugs Ther. 1995 Aug 4; 37(954):67-70
Tuberculosis (TB) continues to be a major problem in the United States, particularly in areas where drug resistance is common (Morbid Mortal Weekly Rep, 44:387, May 26, 1995). Since poor compliance is the most important cause of treatment failure and is associated with emergence of drug resistence, some experts now recommend that all patients take drugs for TB under direct observation (SE Weis et al, N Engl J Med, 330:1179, 1994; R Bayer and D Wilkinson, Lancet, 345:1545, June 17, 1995).
Nefazodone ( Serzone - Bristol-Myers Squibb) was recently approved by the US Food and Drug Administration for treatment of depression. A phenylpiperazine, nefazodone is chemically related to trazodone…
Med Lett Drugs Ther. 1995 Apr 14; 37(946):33-5
Nefazodone ( Serzone - Bristol-Myers Squibb) was recently approved by the US Food and Drug Administration for treatment of depression. A phenylpiperazine, nefazodone is chemically related to trazodone (Desyrel, and others).
A condom for women ( Reality - Wisconsin Pharmacal) to prevent pregnancy and sexually transmitted diseases, including AIDS, has been approved for marketing by the US Food and Drug Administration (FDA). Already…
Med Lett Drugs Ther. 1993 Dec 24; 35(912):123-4
A condom for women ( Reality - Wisconsin Pharmacal) to prevent pregnancy and sexually transmitted diseases, including AIDS, has been approved for marketing by the US Food and Drug Administration (FDA). Already available in many family planning clinics, it will be available in pharmacies in a few months.
The rising incidence of tuberculosis (TB) has been accompanied by a dramatic increase in drug resistance in some areas of the USA (TR Frieden et al, N Engl J Med, 328:521, 1993). Since poor compliance is the…
Med Lett Drugs Ther. 1993 Oct 29; 35(908):99-102
The rising incidence of tuberculosis (TB) has been accompanied by a dramatic increase in drug resistance in some areas of the USA (TR Frieden et al, N Engl J Med, 328:521, 1993). Since poor compliance is the most important cause of treatment failure and associated with emergence of drug resistance, some experts now recommend that patients with TB take their drugs under direct obeservation (MD Iseman et al, N Engl J Med, 329:576, 1993).
The commonly used methods of reversible contraception are listed in the table below. Additional information is available in RA Hatcher et al, Contraceptive Technology , 1990-1992, 15th ed, New York:Irvington,…
Med Lett Drugs Ther. 1992 Dec 11; 34(885):111-4
The commonly used methods of reversible contraception are listed in the table below. Additional information is available in RA Hatcher et al, Contraceptive Technology , 1990-1992, 15th ed, New York:Irvington, 1990.
After many years of decline in the USA, the incidence of tuberculosis (TB) has recently increased, partly because the disease occurs more frequently in patients with human immunodeficiency virus (HIV)…
Med Lett Drugs Ther. 1992 Feb 7; 34(863):10-2
After many years of decline in the USA, the incidence of tuberculosis (TB) has recently increased, partly because the disease occurs more frequently in patients with human immunodeficiency virus (HIV) infection and in the homeless (PF Barnes et al, N Engl J Med, 324:1644, 1991; Morbid Mortal Weekly Rep, 40:869, Dec 20, 1991).
The Norplant System (Wyeth-Ayerst) for subdermal delivery of the synthetic progestin levonorgestrel was recently approved by the US Food and Drug Administration for use as a long-term contraceptive.
Med Lett Drugs Ther. 1991 Mar 8; 33(839):17-8
The Norplant System (Wyeth-Ayerst) for subdermal delivery of the synthetic progestin levonorgestrel was recently approved by the US Food and Drug Administration for use as a long-term contraceptive.
Nafarelin acetate ( Synarel - Syntex), a synthetic analog of gonadotropin-releasing hormone (GnRH), was recently approved by the US Food and Drug Administration for treatment of endometriosis. The drug is…
Med Lett Drugs Ther. 1990 Aug 24; 32(825):81-2
Nafarelin acetate ( Synarel - Syntex), a synthetic analog of gonadotropin-releasing hormone (GnRH), was recently approved by the US Food and Drug Administration for treatment of endometriosis. The drug is available only in a nasal spray formulation.
High doses of various hormones have been used for many years to prevent pregnancy after unprotected coitus. Diethylstilbestrol (DES), a synthetic estrogen, was once approved for this purpose by the US Food and…
Med Lett Drugs Ther. 1989 Oct 20; 31(803):93-4
High doses of various hormones have been used for many years to prevent pregnancy after unprotected coitus. Diethylstilbestrol (DES), a synthetic estrogen, was once approved for this purpose by the US Food and Drug Administration (Medical Letter 15:58, 1973), but no drug is now approved for such use. Ovral , an oral contraceptive containing 50 g of the estrogen ethinyl estradiol and 0.5 mg of the progestin norgestrel, has been recommended as a 'morning-after' pill by some physicians (RA Hatcher et al, Contraceptive Technology 1988-1989, 14th ed., New York:Irvington, 1988, page 374).
Patients with Parkinson's disease have a deficiency of the neurotransmitter dopamine, a catecholamine. Dpamine itself cannot be used to treat the disease because it does not cross the blood-brain barrier, but…
Med Lett Drugs Ther. 1988 Dec 16; 30(781):113-6
Patients with Parkinson's disease have a deficiency of the neurotransmitter dopamine, a catecholamine. Dpamine itself cannot be used to treat the disease because it does not cross the blood-brain barrier, but its metabolic precursor, levodopa, does cross into the brain and is converted to dopamine by a decarboxylase present both in the brain and in the intestinal tract (JM Cedarbaum, Clin Pharmacokinet, 13:141, 1987).
The commonly used methods of reversible contraception are listed in the table. Additional information on the following pages and RA Hatcher et al, Contraceptive Technology, 1988-1989 , 14th ed, New…
Med Lett Drugs Ther. 1988 Nov 18; 30(779):105-8
The commonly used methods of reversible contraception are listed in the table. Additional information on the following pages and RA Hatcher et al, Contraceptive Technology, 1988-1989 , 14th ed, New York:Irvington, 1988.
The US Food and Drug Administration recently approved the marketing of a cervical cap ( Prentif Cavity-Rim Cervical Cap - Lamberts Ltd, England), a contraceptive device that has been used in one form or…
Med Lett Drugs Ther. 1988 Oct 7; 30(776):93-4
The US Food and Drug Administration recently approved the marketing of a cervical cap ( Prentif Cavity-Rim Cervical Cap - Lamberts Ltd, England), a contraceptive device that has been used in one form or another for many years (JP Koch, Contraception, 25:161, 1982). The cap is being distributed in the USA and Canada by Cervical Cap (CxC), Ltd, PO Box 38003-292, Los Gatos, CA 95031, telephone 408-358-6264; the distributor will make the caps available only to practitioners who have attended training seminars.
After many years of decline, the incidence of tuberculosis has recently increased because the disease occurs in patients with AIDS (Morbid Mortal Weekly Rep, 36:817, Jan 1, 1988). For uncomplicated…
Med Lett Drugs Ther. 1988 Apr 8; 30(763):43-4
After many years of decline, the incidence of tuberculosis has recently increased because the disease occurs in patients with AIDS (Morbid Mortal Weekly Rep, 36:817, Jan 1, 1988). For uncomplicated tuberculosis, the recent trend in tuberculosis treatment has been toward a shorter period of therapy and increased use of pyrazinamide.
The copper T 380A ( ParaGard - GynoPharma), a new intrauterine contraceptive device (IUD) soon to be marketed in the USA, will be one of only two IUDs available in this country. Progestasert (Alza), which…
Med Lett Drugs Ther. 1988 Feb 26; 30(760):25-6
The copper T 380A ( ParaGard - GynoPharma), a new intrauterine contraceptive device (IUD) soon to be marketed in the USA, will be one of only two IUDs available in this country. Progestasert (Alza), which gradually releases progesterone (Medical Letter, 18:65, 1976), is the other.